0.4992

2.82% -0.0145

After Hours: .50 0.0008 +0.16%

Pasithea Therapeutics Corp (KTTA)

Overview News Price History Financials Discussions Forecast

Pasithea Therapeutics Corp stock is traded at $0.4992, with a volume of 94,762. It is down -2.82% in the last 24 hours and down -10.86% over the past month. Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.

Previous Close:

$0.5137

Open:

$0.5

24h Volume:

94,762

Relative Volume:

0.15

Market Cap:

$16.68M

Revenue:

Net Income/Loss:

$-19.73M

P/E Ratio:

-0.2407

EPS:

-2.0742

Net Cash Flow:

$-16.94M

1W Performance:

-4.68%

1M Performance:

-10.86%

6M Performance:

-36.11%

1Y Performance:

-29.68%

1-Day Range:

$0.4852

$0.5097

1-Week Range:

$0.4852

$0.5298

52-Week Range:

$0.281

$2.06

Pasithea Therapeutics Corp Stock (KTTA) Company Profile

Name

Pasithea Therapeutics Corp

Sector

Healthcare (1067)

Industry

Biotechnology (595)

Phone

(702) 514-4174

Address

1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH

Employee

Twitter

Next Earnings Date

2026-11-12

Latest SEC Filings

KTTA's Discussions on Twitter

Compare KTTA vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KTTA Pasithea Therapeutics Corp	0.4992	16.68M	0	-19.73M	-16.94M	-2.0742
VRTX Vertex Pharmaceuticals Inc	526.19	133.37B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	788.04	81.13B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	198.88	79.40B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	959.49	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	204.97	43.93B	742.00K	-1.37B	-1.07B	-7.0731

Pasithea Therapeutics Corp Stock (KTTA) Latest News

Sep 18, 2026

Pasithea Therapeutics Announces Nasdaq Warrant Expiration - TipRanks

Sep 18, 2026

Sep 17, 2026

Pasithea Therapeutics Corp.Common Stock (Nasdaq:KTTA) Price Chart - The Chronicle-Journal

Sep 17, 2026

Sep 16, 2026

Pasithea Therapeutics warrants to expire Sept. 17, 2026; delisting and deregistration planned - TradingView

Sep 16, 2026

Pasithea Therapeutics (NASDAQ: KTTA) says KTTAW warrants will lose all value - Stock Titan

Sep 16, 2026

Pasithea Therapeutics (NASDAQ: KTTA) withdraws its warrants from Nasdaq listing - Stock Titan

Sep 16, 2026

Sep 15, 2026

Pasithea Therapeutics Slides As Insider Purchases Lose Another US$48k - simplywall.st

Sep 15, 2026

Sep 14, 2026

Pasithea Therapeutics to Present Initial PAS-004 Clinical Data in Oral and Poster Sessions at 2026 European Neurofibromatosis Conference - Quiver Quantitative

Sep 14, 2026

A nerve-tumor drug trial’s first clinical data will be presented in Vienna this November - Stock Titan

Sep 14, 2026

Sep 10, 2026

Pasithea Therapeutics Corp. Warrant (KTTAW) Peer Comparison – Compare with Others - Value Research

Sep 10, 2026

Sep 09, 2026

Pasithea Therapeutics Shareholders Approve Reverse Stock Split - TipRanks

Sep 09, 2026

Sep 03, 2026

Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences - Yahoo! Finance Canada

Sep 03, 2026

Aug 28, 2026

Enterprise value to revenue forward of Pasithea Therapeutics Corp. – NASDAQ:KTTAW - TradingView

Aug 28, 2026

Aug 22, 2026

Pasithea Therapeutics Receives Nasdaq Extension on Listing Compliance - The Globe and Mail

Aug 22, 2026

Aug 21, 2026

Pasithea Therapeutics Received Notice of Noncompliance - TradingView

Aug 21, 2026

Pasithea (NASDAQ: KTTA) gets Nasdaq reprieve before possible delisting - Stock Titan

Aug 21, 2026

Aug 19, 2026

Pasithea (KTTA) Q1 2026 Earnings: EPS Clears the Reported Estimate; Session Move: The Stock Ends Down 1.21% in the Latest ReadingLow Growth Earnings - vinanet.vn

Aug 19, 2026

Aug 14, 2026

Pasithea Therapeutics Company Profile & Introduction - Moomoo

Aug 14, 2026

Pasithea Therapeutics Corp reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 14, 2026

Pasithea Therapeutics Corp. Q2 2026: Net loss $(5.27M), EPS $(0.16) — 10-Q Summary - TradingView

Aug 14, 2026

KTTA: Q2 2026 net loss rose to $5.27M as R&D spending surged; cash reserves at $45.7M - TradingView

Aug 14, 2026

Vivo Opportunity entities disclose 9.99% Pasithea Therapeutics (KTTA) holdings via warrants and stock - Stock Titan

Aug 14, 2026

Aug 13, 2026

KTTA Q1 2026 Earnings: Narrower-than-Expected Loss of $0.12 Per Share Highlights Cost ControlProduct Revenue Analysis - dars.gov.et

Aug 13, 2026

Aug 11, 2026

KTTA Q1 2026 Earnings: Deep Loss Narrowing Beats Estimates by Wide MarginEarnings Season Preview - dars.gov.et

Aug 11, 2026

Enterprise value to EBIT forward of Pasithea Therapeutics Corp. – NASDAQ:KTTAW - TradingView

Aug 11, 2026

Aug 10, 2026

Pasithea Therapeutics Corp expected to post a loss of 16 cents a shareEarnings Preview - TradingView

Aug 10, 2026

Aug 08, 2026

Pasithea Therapeutics (KTTA) Jumps 14% as Price Approaches Key ResistanceFibonacci Time Zone - vinanet.vn

Aug 08, 2026

Aug 07, 2026

Pasithea Therapeutics (KTTA) Edges Higher: Micro-Cap Biotech Approaches Key Resistance at $0.48TRIN Signal - vinanet.vn

Aug 01, 2026

Jul 31, 2026

Opaleye group (NASDAQ: KTTA) discloses 6.14% Pasithea Therapeutics ownership in 13G/A - stocktitan.net

Jul 31, 2026

Jul 29, 2026

Pasithea Therapeutics (NASDAQ: KTTA) sets virtual 2026 meeting and reverse split vote - Stock Titan

Jul 29, 2026

Jul 28, 2026